Latest Insider Transactions at Heron Therapeutics, Inc. (HRTX)
This section provides a real-time view of insider transactions for Heron Therapeutics, Inc. (HRTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of HERON THERAPEUTICS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of HERON THERAPEUTICS, INC. 's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 13
2021
|
John Poyhonen President & CCO |
SELL
Payment of exercise price or tax liability
|
Direct |
433
-2.08%
|
$6,928
$16.66 P/Share
|
|
Apr 13
2021
|
John Poyhonen President & CCO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+5.66%
|
-
|
|
Apr 13
2021
|
David Leslie Szekeres EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
433
-34.64%
|
$6,928
$16.66 P/Share
|
|
Apr 13
2021
|
David Leslie Szekeres EVP, Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+50.0%
|
-
|
|
Apr 13
2021
|
Barry D Quart Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
963
-1.0%
|
$15,408
$16.66 P/Share
|
|
Apr 13
2021
|
Barry D Quart Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,646
+3.65%
|
-
|
|
Apr 06
2021
|
Craig A Johnson Director |
SELL
Open market or private sale
|
Direct |
250
-6.51%
|
$4,250
$17.22 P/Share
|
|
Jan 14
2021
|
David Leslie Szekeres EVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
827
-100.0%
|
$14,886
$18.09 P/Share
|
|
Jan 13
2021
|
Kimberly Manhard EVP, Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
433
-34.64%
|
$7,794
$18.16 P/Share
|
|
Jan 13
2021
|
Kimberly Manhard EVP, Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+50.0%
|
-
|
|
Jan 13
2021
|
Lisa Peraza VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
227
-1.92%
|
$4,086
$18.16 P/Share
|
|
Jan 13
2021
|
Lisa Peraza VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
552
+4.46%
|
-
|
|
Jan 13
2021
|
John Poyhonen President & CCO |
SELL
Payment of exercise price or tax liability
|
Direct |
433
-2.16%
|
$7,794
$18.16 P/Share
|
|
Jan 13
2021
|
John Poyhonen President & CCO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+5.87%
|
-
|
|
Jan 13
2021
|
Barry D Quart Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
963
-1.04%
|
$17,334
$18.16 P/Share
|
|
Jan 13
2021
|
Barry D Quart Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,646
+3.78%
|
-
|
|
Jan 13
2021
|
David Leslie Szekeres EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
423
-33.84%
|
$7,614
$18.16 P/Share
|
|
Jan 13
2021
|
David Leslie Szekeres EVP, Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+50.0%
|
-
|
|
Jan 08
2021
|
David Leslie Szekeres EVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,571
-100.0%
|
$67,849
$19.66 P/Share
|
|
Dec 22
2020
|
Kimberly Manhard EVP, Drug Development |
SELL
Open market or private sale
|
Direct |
10,000
-100.0%
|
$200,000
$20.0 P/Share
|
|
Dec 22
2020
|
Kimberly Manhard EVP, Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$130,000
$13.0 P/Share
|
|
Dec 21
2020
|
Stephen Davis Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+50.0%
|
-
|
|
Dec 21
2020
|
Craig A Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+43.86%
|
-
|
|
Dec 21
2020
|
Waage Christian Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+40.54%
|
-
|
|
Oct 30
2020
|
John Poyhonen President & CCO |
BUY
Other acquisition or disposition
|
Direct |
637
+3.28%
|
$7,007
$11.65 P/Share
|
|
Apr 30
2020
|
Barry D Quart Chief Executive Officer |
BUY
Other acquisition or disposition
|
Direct |
1,158
+1.28%
|
$13,896
$12.12 P/Share
|
|
Oct 04
2019
|
Tang Kevin C Director |
BUY
Open market or private purchase
|
Indirect |
285,714
+4.7%
|
$4,857,138
$17.5 P/Share
|
|
Sep 12
2018
|
Tang Kevin C Director |
SELL
Open market or private sale
|
Indirect |
2,695,000
-31.61%
|
$94,325,000
$35.75 P/Share
|
|
Mar 29
2018
|
Tang Kevin C Director |
BUY
Open market or private purchase
|
Indirect |
192,308
+2.21%
|
$5,000,008
$26.0 P/Share
|
|
Nov 04
2016
|
Barry D Quart Chief Executive Officer |
BUY
Bona fide gift
|
Direct |
600
+0.64%
|
-
|
|
Nov 04
2016
|
Barry D Quart Chief Executive Officer |
SELL
Bona fide gift
|
Indirect |
600
-100.0%
|
-
|
|
Jun 20
2015
|
Barry D Quart Chief Executive Officer |
BUY
Other acquisition or disposition
|
Indirect |
600
+50.0%
|
-
|